Sign in

Morgan Lamberti

Research Analyst at Goldman Sachs

Morgan Lamberti is an Equity Research Associate at Goldman Sachs, specializing in biotechnology sector coverage with a focus on companies such as Krystal Biotech. As part of the equity research team, Lamberti supports senior analysts in producing actionable investment insights and financial analysis, contributing to coverage of high-performing biotech firms. Lamberti began working at Goldman Sachs after completing advanced academic training, and currently leverages a strong analytical background to deliver research that informs investment decisions. Morgan Lamberti holds FINRA registration as a broker and meets the regulatory requirements for securities research roles.

Morgan Lamberti's questions to Krystal Biotech (KRYS) leadership

Morgan Lamberti's questions to Krystal Biotech (KRYS) leadership • Q2 2025

Question

Morgan Lamberti from Goldman Sachs asked if the Japan launch would require an initial healthcare practitioner visit and requested details on the fifth patient dosed in the AATD study.

Answer

Chairman & CEO Krish Krishnan confirmed the Japan launch process is similar to Europe, requiring an initial physician visit. President of R&D Suma Krishnan noted that across all three bronchoscopy patients, they saw robust expression in biopsy samples, and in two of those patients, they were able to measure AAT in the lavage and see a reduction in neutrophil elastase.

Ask Fintool Equity Research AI